SETD2 and neoplasm: Mutation of the histone H3 lysine 36 histone (H3K36) methyltransferase gene SETD2 may produce dysfunction in corresponding tumour tissue proteins, leading to tumorigenesis, progression, chemotherapy resistance, and unfavourable prognosis [16].